----item----
version: 1
id: {966F8214-2C42-459A-8668-E95B061DD047}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/05/06/Titan plans 2nd half Probuphine resubmission on new data
parent: {338890BA-77DA-453B-BF49-385B6ACAE152}
name: Titan plans 2nd half Probuphine resubmission on new data
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 897a5d6f-bddc-4b01-8cd6-fd6ad925b36e

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 56

Titan plans 2nd half Probuphine resubmission on new data
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 56

Titan plans 2nd half Probuphine resubmission on new data
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2068

<p>With new positive Phase III results in hand, Titan Pharmaceuticals on 8 June said it will be ready by the second half of this year to resubmit its new drug application (NDA) to the FDA for Probuphine (buprenorphine hydrochloride/ethylene vinyl acetate), a subdermal implant that's under investigation as a maintenance treatment for opioid addiction.</p><p>Shares of Titan soared nearly 24% on 8 June, before closing at 89 cents, up 11.7%, or 9 cents.</p><p>Top-line results from a double blind, double dummy Phase III study of Probuphine met the prespecified primary endpoint of noninferiority, plus all secondary efficacy endpoints, the firm reported. </p><p>The study was conducted by Titan's commercialization and development partner Braeburn Pharmaceuticals and was designed and developed in consultation with the FDA. </p><p>The study enrolled 177 patients who were randomized to receive either the Probuphine implants or sublingual tablets for a treatment period of six months. </p><p>The objective of the study was to show noninferiority between the two treatment groups.</p><p>Analyses indicated response rates of 96.4% for the Probuphine arm, versus 87.6% for the sublingual buprenorphine/naloxone arm. </p><p>The FDA in <a href="http://www.scripintelligence.com/home/FDA-rejects-Probuphine-Mayday-Mayday-Mayday-for-Titan-shares-342735" target="_new">April 2013 rejected</a> the NDA for Probuphine, declaring the companies needed to provide <a href="http://www.scripintelligence.com/policyregulation/FDA-path-forward-for-Probuphine-requires-study-Titan-tumbles-348991" target="_new">more data</a> before the agency could consider the application.</p><p>If approved by the FDA, Probuphine would be the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single procedure. </p><p>There are 2.2 million people in the US with opioid addiction &ndash; 80% of whom are addicted to prescription opioids, such as oxycodone, hydrocodone, methadone, hydromorphone and codeine. </p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 356

<p>With new positive Phase III results in hand, Titan Pharmaceuticals on 8 June said it will be ready by the second half of this year to resubmit its new drug application (NDA) to the FDA for Probuphine (buprenorphine hydrochloride/ethylene vinyl acetate), a subdermal implant that's under investigation as a maintenance treatment for opioid addiction.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 56

Titan plans 2nd half Probuphine resubmission on new data
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150506T160000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150506T160000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150506T160000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028940
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 56

Titan plans 2nd half Probuphine resubmission on new data
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

headline news
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358764
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042400Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

897a5d6f-bddc-4b01-8cd6-fd6ad925b36e
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042400Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
